Log in to post a reply
Apr 7, 2018 10:46AM
Apr 8, 2018 03:04PM
That is really strange that there is no research about women with negative lymph nodes, low grade, stage 1 breast cancer, but if you think about it, not so strange. The probability is very high that they do have the numbers but there is no money incentive to release them to the public. When there is that much money involved (radiation is thousands of dollars and I don't know the generic Tamoxifen costs), you can never rely on human decency and you have to do your research. The older you are, the less aggressive they are in treating the cancer if it's small and low grade, so suburban Philadelphia, I am not surprised your cancer did not return and that you chose the path you did. If you get cancer in your 40's and you still have about 40 years to live, the probability is higher for cancer cells to reappear because the hormone levels are much higher and there is more time left. A lot more can happen to you in a 40 year time span than lets say a 10-20 year time-span. I think even as far as family history goes, if you notice, they always ask at what age your mother/sister/grandmother received the breast cancer. That is a very important element. Jons girl, what was the recurrence rate that you were told? Also, much luck to you with continued health and I don't think you are crazy in your choice, you are entitled to it and the risks are high with meds/radiation too. The meds and radiation both can cause cancer!!!
PS I was 52 and 5 months when my breast biopsy came back positive for invasive ductile carcinoma and so I was right on the borderline in terms of timing in the midst of my lifespan. Medicine is not a black and white science like mathematics, but very grey and lots of shade of gray, so no decision is right or wrong, but somewhere in the spectrum. That's what makes decision making so tough.
Transitioning Endoxifen to Clinical Trials
Our next step was to develop endoxifen into a drug that could be administered to humans. But because its chemical structure was already public knowledge, there was limited interest in its drug development by pharmaceutical companies.
NCI, however, was in a position to step in again. As a part of its broad mission to bolster cancer research, NCI is uniquely qualified to develop promising new treatments or drugs that have limited potential for commercialization.
With promising results from these preclinical studies, NCI filed an Investigational New Drug application for endoxifen with the Food and Drug Administration (FDA) so that clinical trials could begin.
Through NCI's Cancer Therapy Evaluation Program and clinical trials program, Mayo Clinic and NCI launched the first phase I trials of endoxifen in 2011 in women with metastatic breast cancer whose tumors had progressed following treatment with aromatase inhibitors and tamoxifen.
In 2015, we initiated a randomized phase II trial comparing how well endoxifen and tamoxifen work in women with breast cancer, with results expected in early 2018. The trial is sponsored by NCI's Cancer Therapy Evaluation Program and is conducted by the Alliance for Clinical Trials in Oncology, an NCI-funded clinical trials group.
It's not yet clear how this endoxifen story will end. Drug development is costly and time consuming, and there's no way to know if a drug will benefit patients until it is rigorously tested in multiple clinical trials.
What is clear, however, is that without the commitment and collaborative spirit of the Mayo team—including James Ingle, M.D., Matthew Ames, Ph.D., Joel Reid, Ph.D., Thomas Spelsberg, Ph.D., and John Hawse, Ph.D.—and NCI's continuous support, this potentially promising therapy might never have been developed. I'm thankful to have come this far with our story, and am hopeful that our efforts will ultimately lead to beneficial results for patients.